Bromide

Bromide

SCHEMBL2818240

C[Si](C)(C)Cl.[Br-].[Li+]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL9837092 0.88
Lithium Ion SCHEMBL6862804 0.88
SCHEMBL1319 0.87
SCHEMBL15658212 0.87 ALDH1A1 (1.00)
SCHEMBL9419675 0.80
Hydrochloric Acid SCHEMBL7512029 0.80
SCHEMBL9357181 0.80 ALDH1A1 (0.86)
SCHEMBL8715381 0.80
Water SCHEMBL8878056 0.80 ALDH1A1 (0.86)
Charcoal, Activated SCHEMBL8413635 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858761-B2 1-α-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivatives and process for the preparation thereof HANMI PHARM. CO., LTD (KR) 2010-12-28 US claimed
US-20070238865-A1 intermediates in preparation of gemcitabine in large scale; reducing 1-oxoribose compound to obtain actol compound, reacting with halophosphate compound in presence of base to obtain a 1-phosphate furanose derivative, reacting with halide source, then crystallizing HANMI PHARM CO., LTD (KR) 2007-10-11 US claimed
EP-1781678-A1 1-ALPHA-HALO-2,2-DIFLUORO-2-DEOXY-D-RIBOFURANOSE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Hanmi Pharm. Co., Ltd. (KR) 2007-05-09 EP claimed
WO-2006011713-A1 1-α-HALO-2,2-DIFLUORO-2-DEOXY-D-RIBOFURANOSE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2006-02-02 WO claimed
US-7858761-B2 1-α-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivatives and process for the preparation thereof HANMI PHARM. CO., LTD (KR) 2010-12-28 US disclosed
US-20070238865-A1 intermediates in preparation of gemcitabine in large scale; reducing 1-oxoribose compound to obtain actol compound, reacting with halophosphate compound in presence of base to obtain a 1-phosphate furanose derivative, reacting with halide source, then crystallizing HANMI PHARM CO., LTD (KR) 2007-10-11 US disclosed
EP-1781678-A1 1-ALPHA-HALO-2,2-DIFLUORO-2-DEOXY-D-RIBOFURANOSE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Hanmi Pharm. Co., Ltd. (KR) 2007-05-09 EP disclosed
WO-2006011713-A1 1-α-HALO-2,2-DIFLUORO-2-DEOXY-D-RIBOFURANOSE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2006-02-02 WO disclosed